Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.

Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Objectives: To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis.

Methods: PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily.

The fundamentals of multiplicity adjustment in biostatistics.

The statistical problem of multiplicity is concerned with making protected multiple inferences and their valid interpretation in a particular study. Most discussions of multiplicity focus on the increase of type I error rate if testing is done without any adjustment, with only a few papers discussing its ramifications for type II errors/power. We provide a survey of main approaches to protected inference in biomedical studies, touching on procedures to control the family-wise error rate, false discovery rate, as well as false discovery exceedance probability.

Study characteristics and methods in a national nursing and allied health research programme: A descriptive study.

Aim: To describe the characteristics, methods and publications of studies funded by a French research programme for nursing and allied health professions.

Background: In some countries, the emerging field of nursing and allied health research is supported by funding programmes that are poorly documented.

Design: Observational descriptive study.

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.

Importance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.

Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.

Design, Setting, And Participants: PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis.

Testosterone variation in a semi-captive population of Asian elephants in Myanmar.

Hormones are known to be involved in life-history trade-offs as systemic signals that establish functional links among traits and regulate key behavioural and physiological transitions between states in organisms. Although major functions of many steroid hormones such as testosterone are conserved among vertebrates, circulating concentrations vary widely both within and across species, and the degree to which observed hormone concentrations mediate life-history responses to environmental variation is less understood. In this study, we investigated how faecal testosterone metabolite (FTM) concentrations varied with extrinsic and intrinsic factors.